StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Up 6.0 % NASDAQ:AKTX opened at $3.16 on Monday. The company has a 50-day moving average of $3.56 and a 200-day moving […]

Leave a Reply

Your email address will not be published.

Previous post Braze (NASDAQ:BRZE) Rating Reiterated by JMP Securities
Next post Cantor Fitzgerald Reaffirms “Neutral” Rating for Booking (NASDAQ:BKNG)